Objective: We evaluated the impact of Option A on HIV-free infant survival and mother-to-child transmission (MTCT) in Zimbabwe.
Introduction
New pediatric HIV infections globally declined by 58% between 2000 and 2014 [1] , largely due to the implementation of increasingly efficacious drug regimens for the prevention of mother-to-child transmission (PMTCT) of HIV. Nonetheless, in 2014, 220 000 children became infected with HIV worldwide, and 190 000 of them were in sub-Saharan Africa [1] . The WHO has regularly updated their PMTCT guidelines for developing countries, in response to new evidence about the efficacy of PMTCT regimens. In 2010, WHO recommended Option A, namely HIV-infected pregnant women eligible for antiretroviral therapy (ART, i.e. CD4 þ cell count 350 cells/ml or Stage 3-4 disease) receive lifelong therapy and ART-ineligible women (i.e. CD4 þ cell count >350 cells/ml and Stage 1-2 disease) receive antiretroviral prophylaxis during pregnancy (starting at 14 weeks), labor and postpartum; their infants also receive prophylaxis throughout breastfeeding [2] . In 2013, WHO updated their guidelines, recommending that all pregnant women, regardless of clinical stage, receive ART at a minimum during pregnancy and breastfeeding (Option B) or ideally lifelong (Option Bþ) [3] .
Many developing countries have adopted the 2010 or the 2013 WHO-recommended regimens [4] and have aligned themselves with the global goal to achieve virtual elimination of mother-to-child transmission (MTCT) (MTCT < 5%) by 2015 [5] . Consequently, there are increased efforts in monitoring countries' progress toward this goal. There is little empirical evidence of the population-level impact of Option A on reducing MTCT. Although WHO guidelines have shifted to Option Bþ, documenting the effectiveness of Option A provides a baseline against which to evaluate the impact of Option Bþ and to identify implementation issues relevant for ongoing PMTCT programing.
We assessed the impact of Option A on MTCT, using data from Zimbabwe where 16% of pregnant women were estimated to be HIV-infected in 2012 [6] , and 10% of their infants were estimated to be infected in 2013 [7] . We conducted an impact evaluation of this PMTCT program in parallel with the implementation of Option A, which began in 2011, using two population-based crosssectional serosurveys of mother-infant pairs (in 2012 and 2014). We previously reported the estimates from the baseline survey [8, 9] . Here we present the impact evaluation results that had the following objectives: estimate the impact of Option A in Zimbabwe on MTCT and HIV-free infant survival at 9-18 months after 2 years of implementation and determine whether the effects were stronger in catchment areas where Option A was established earlier.
Methods
Zimbabwe's prevention of mother-to-child transmission program In 2011, the Zimbabwe Ministry of Health and Child Care (MoHCC) adopted and implemented Option A nationally. MoHCC distributed point-of-care CD4 þ cell count testing machines for determination of ART eligibility and facilitated community mobilization to increase entry and retention in the PMTCT cascade. UNAIDS commended the Zimbabwe MoHCC for this successful countrywide implementation [10] , Zimbabwe began rollout of Option Bþ in November 2013.
Study design
We conducted two cross-sectional population-representative surveys of mother-infant pairs in five of Zimbabwe's 10 provinces to estimate the difference in catchment area level MTCT and HIV-free infant survival before and after Option A implementation ( Fig. 1 ). Detailed methodology for this study has been previously described [8, 9] .
Study population
The study population consisted of infants born 9-18 months before the survey and their biological mothers or caregivers aged at least 16 years old (henceforth called 'mother-infant pairs'). We included infants 9-18 months old to be able to detect HIV transmissions occurring during pregnancy, delivery, and breastfeeding [2] . To estimate the impact of Option A, the study population was limited to HIV-infected women and their infants.
Sampling strategy
Eligible mother-infant pairs were selected using a threestage sampling strategy: selection of provinces, facility catchment areas, and mother-infant pairs.
Stage 1
We selected five of Zimbabwe's 10 provinces (Harare, Mashonaland West, Mashonaland Central, Manicaland, and Matabeleland South), as resources for the evaluation precluded sampling the entire country. These included three of the four largest cities in Zimbabwe, rural communities with high and low HIV prevalence, areas where detailed monitoring data were being collected, and representation of both major ethnic groups in Zimbabwe (Shona, Ndebele).
Stage 2
In 2012, we randomly selected 157 out of 699 catchment areas of health facilities in these provinces where PMTCT services were available. At each facility, in a selected catchment area, we administered a questionnaire with head nurses to capture the services delivered at that facility and the timing of Option A rollout. The catchment areas of these facilities, which are geographical areas defined by the MoHCC, were primary sampling units and were randomly sampled proportionate to the number of catchment areas in their district. Stage 3 In each sampled catchment area, we identified all eligible infants and sampled a predetermined fraction of them with the objective of enrolling 50 infants per catchment area (according to our power calculations). Infants born in the previous 2 years were identified on the basis of information pooled from community health workers and immunization registers from selected facilities and neighboring facilities (to identify women residing in sampled facilities who accessed services at adjacent facilities). Further, mothers, identified using either method, were asked to identify other eligible infants in their neighborhood. This three-pronged approach efficiently identified eligible participants without screening all the households in the selected catchment areas and captured mother-infant pairs who received care outside their area of residence.
Data collection
Participating mothers/caregivers answered intervieweradministered questionnaires capturing mothers' experience of health services. If participants had medical records in their possession (i.e. infant/maternal health card), interviewers collected documented information on HIV status. Living biological mothers and infants provided dried blood spot samples for HIV testing. If the biological mother of an eligible infant was deceased, we interviewed the caregiver to ascertain the probable cause of death. If the eligible infant was deceased, we interviewed the mother to assess the baby's likely cause of death. We used adapted verbal autopsy questionnaires developed by WHO [11] .
Laboratory procedures Maternal samples were tested for HIV-1 antibody, using AniLabsytems EIA kit (AniLabsystems Ltd, OyToilette 3, FIN-01720 Vantaa, Finland) with all positive specimens confirmed using Enzygnost Anti-HIV 1/2 and ELISA (Dade Behring, Marburg, Germany) and discrepant results resolved by western blot. We tested the samples of infants born to HIV-positive mothers and to mothers whose sample was unavailable; infant samples were tested for HIV with DNA PCR (Roche Amplicor HIV-1 DNA Test 1.5).
Indicators and outcomes

Primary outcomes
We estimated two outcomes:
(1) HIV-free infant survival (catchment area level proportion of infants 9-18 months of age who were born to HIV-infected mothers and who were alive and HIV- 
Statistical analysis
Objective 1
We assessed Option A impact by estimating the differences in catchment area level MTCT and HIVfree infant survival at 9-18 months. Because we were interested in the population effect of Option A implemented at facility-level, we conducted catchment area level analysis (rather than individual-level analysis), consistent with the study design and power calculations. We calculated catchment area level MTCT and HIV-free infant survival at both time points, and used a paired t test to estimate the mean change in these unadjusted proportions in each catchment area between the 2012 and the 2014 surveys.
Although the order in which communities were surveyed in 2012 was timed to maximize the likelihood that all participating infants were born before rollout of Option A, in some catchment areas, Option A had been implemented before eligible infants were born (see Figure, Appendix, http://links.lww.com/QAD/A914). We excluded these catchment areas from the analysis, specifically catchment areas where Option A was implemented before the mean birthdate of infants surveyed in 2012 and one additional catchment area where the timing of Option A rollout was unavailable.
We also estimated the number of infant HIV infections averted because of Option A, using maternal prevalence and MTCT rates. First, we estimated infant infections averted compared with the lack of any PMTCT regimen, by subtracting the number of infections in 2014 from the estimated number of infections in the absence of PMTCT (assuming 35% MTCT) [5] . Second, we estimated infant infections averted compared with pre-Option A levels, by subtracting the number of infections in 2014 from the number of infections at Option A baseline (applying the MTCT rate in the 2012 survey). All estimates of infant infections were calculated assuming maternal HIV prevalence rates from our evaluation and the number of pregnant women in Zimbabwe from MoHCC.
Objective 2
We examined whether the length of exposure to Option A in each catchment area was associated with a difference in catchment area level HIV-free survival. First, we examined the number of months that Option A had been implemented in each catchment area and its bivariatelevel association with the catchment area level HIV-free survival at endline using ANOVA. We also examined this association at the multivariate level using a generalized linear model with a logit link controlling for HIV-free survival at baseline, urban vs. rural catchment area, number of health staff, number of days per week the facility is open for ANC, the proportion of staff that received training on Option A, and whether the facility had on site CD4 þ cell count testing at baseline. Of the characteristics initially examined, we excluded some highly correlated variables (estimated population, number of rooms in facility, number of HIV-infected mothers, maternal HIV prevalence).
The data were analyzed in STATA 12 (STATA Corp., College Station, Texas, USA) and SAS 9.4 (SAS Institute Inc., Cary, North Carolina, USA), and all data were weighted to adjust for differences in the sampling fraction of catchment areas within districts.
Sample size calculation
Our sample size was determined to detect a reduction in the catchment area level proportion of HIV-exposed infants who either died or became infected with HIV (our primary outcome) from 25 (22-30%) [13] to 18.75%, assuming an estimated HIV prevalence in 16-49-yearold pregnant women of 16% [14] . Our estimates assumed 95% significance and 80% power and were rounded up to the nearest integer. In the absence of reliable data on the coefficient of variation for MTCT by catchment area in this population, a conservative value of 0.25 was assumed [15] . Initially, assuming a response rate of 90%, we estimated that we would need to sample 157 catchment areas to achieve the required sample of 7800 motherinfant pairs. Maternal HIV prevalence and MTCT were both lower than expected in the 2012 survey. Thus, for the 2014 survey, we recalculated the necessary sample using the same 157 catchment areas with 80% power to detect a difference to below 5% MTCT (the targeted value for Zimbabwe), and we increased the sampling fraction to maintain a harmonic mean of at least four HIV-exposed infants per catchment area.
In the 2012 survey, we used the following sampling fractions: one in four eligible infants in catchment areas with more than 300 eligible infants, one in two in catchment areas with 150-300 eligible infants, or all eligible infants in catchment areas with less than 150 eligible infants. In 2014, the sampling fractions were revised: one in five in catchment areas with more than 300 eligible pairs, one in four in catchment areas with 250-300 eligible pairs, one in three in catchment areas with 180-249 eligible pairs, one in two in catchment areas with 120-180 eligible pairs, or all eligible pairs in catchment areas with less than 120 eligible pairs.
Human study participants protection
The Medical Research Council of Zimbabwe and the ethics committees of University of California, Berkeley, and University College London approved the study protocol. All participants provided written informed consent and were compensated for their time with a gift worth $5. The biobehavioral data collected in 2012 were anonymous; participants retrieved their anonymous HIV test results at the local facility up to 3 months following the survey, using a card with barcode numbers. In 2014, participants who wanted to receive their HIV test results had to provide identifying information to allow personal identification upon receipt of HIV test results at the local facility.
Results
There were 132 catchment areas classified as unexposed to Option A in the 2012 baseline survey; 7683 motherinfant pairs participated in the 2012 survey and 9283 in the 2014 survey. Response rate was high: 97.4% for maternal blood samples in 2012 and 95.3% in 2014, and 96.5% for infant blood samples in 2012 and 93.5% in 2014. We were able to determine the HIV status for 7249 mothers in 2012 and 8551 mothers in 2014; of these, 887 (12.2%) and 1160 (13.6%) were HIV-infected, respectively.
In 2012, we found an average of 6.5 HIV-exposed infants per catchment area, of whom an average of 0.6 infants were HIV-infected, and an average of 6.0 infants were alive and HIV-uninfected (Table 1) . Thus, in 2012, the mean catchment area level MTCT rate was 10%, and the mean catchment area level HIV-free infant survival was 89.6%. In 2014, in the same 132 catchment areas, we found an average of 8.6 HIV-exposed infants, of whom an average of 0.5 infants were HIV-infected, and an average of 8.2 infants were alive and HIV-uninfected. Hence, in 2014, the mean catchment area level MTCT rate was 4.8%, and the mean catchment area level HIV-free infant survival was 95.1%. No MTCT rate was calculated for the catchment areas with 0 HIV-exposed infants (4 catchment areas at baseline, 2 catchment areas at endline).
The mean difference in the catchment area level MTCT rate at 9-18 months between 2014 and 2012 was À5.2 percentage points [95% confidence interval (CI) ¼ À8.1, À2.3, P < 0.001], representing a 52% reduction ( Table 2 ). The mean difference in the catchment area level HIV-free infant survival at 9-18 months between 2014 and 2012 was 5.5 percentage points (95% CI ¼ 2.6, 8.5, P < 0.001), representing a 6% increase in HIV-free survival. Between 2012 and 2014, we estimated that 31 185 infant HIV infections were averted by Option A compared with the absence of any PMTCT regimen; 1779 infections were averted by Option A compared with the pre-Option A regimen.
At the time of the 2014 survey, the median time since Option A implementation was 36 months (range: 26-40); thus, the median duration of Option A implementation when the survey infants were born was 24 months. HIV-free infant survival was marginally associated with duration of Option A implementation at the bivariate level (P ¼ 0.025); this association remained slightly positive but NS after controlling for population and facility characteristics (P ¼ 0.093, Table 3 ). Among covariates, the only statistically significant variable was urban/rural status, with rural catchment areas experiencing slightly higher HIV-free survival than urban catchment areas (regression coefficient ¼ À0.10, 95% CI:À0.19, À0.01, P ¼ 0.037).
Discussion
We conducted an impact evaluation of Option A of the 2010 WHO guidelines in Zimbabwe, a UNAIDS priority country; 2 years after Option A rollout, we found significantly decreased MTCT and significantly increased HIV-free infant survival at 9-18 months. Introduction of Option A resulted in almost 1800 HIV infant infections being averted. This is the first and only impact evaluation of Option A and shows that Option A has appreciable impact at scale. The data also indicate Zimbabwe's remarkable progress toward eMTCT, despite challenging political and economical conditions. The duration of Option A implementation (median 36, range 26-40 months) was not associated with catchment area level HIV-free survival after controlling for population and facility characteristics.
The efficacy of the PMTCT regimens recommended by the 2010-2013 WHO guidelines has been established [2] . However, little is known about their population effectiveness, especially at scale. To our knowledge, these are the first findings from a large-scale impact evaluation of the recent WHO guidelines for PMTCT in developing countries and the first impact evaluation of Option A.
Only one impact evaluation of the current WHO guidelines has thus far been conducted and showed increased HIV-free survival at 24 months in Zambia, from 66% at baseline to 89% post-Option B (adjusted hazard ratio 0.52) [16] . However, the Zambian evaluation was small scale and assessed a pilot program implementing Option B in four facilities. National-level assessments of the recent WHO guidelines are underway in Rwanda (Option B) [17] , Malawi (Option Bþ) [18] , and South Africa [19] ; however, only the baseline estimates of these evaluations have been published so far [17] [18] [19] .
Our study consisted of two serial cross-sectional community-based serosurveys of mother-infant pairs. This study design, initially used in the four-country PEARL study [20] , has also been used in the abovementioned Zambian [16] and Rwandan [17] evaluations. In contrast, the Malawian and South African assessments consist of serial cross-sectional serosurveys of motherinfant pairs attending childhood immunizations [18, 19] , which can only estimate early MTCT (<3 months) because they do not account for breastfeeding-related transmission. Community-based surveys such as ours are able to assess both MTCT and HIV-free infant survival; include all mother-infant pairs, not just those who use health facilities; and account for HIV infections occurring through breastfeeding (e.g. we assessed these outcomes at 9-18 months of age, the Zambian and Rwandan evaluations assessed outcomes at 24 months) [16, 17] .
1660 AIDS 2016, Vol 30 No 10 Table 2 . Impact of Zimbabwe's prevention of mother-to-child transmission program implementing the 2010 WHO Option A guidelines on mother-to-child transmission and HIV-free infant survival at 9-18 months. Prepost analysis with the catchment area as the unit of analysis. We calculated weighted catchment area level MTCT and HIV-free infant survival at both time points and used a paired t test to estimate the mean change in these unadjusted proportions in each catchment area between the 2012 survey and the 2014 survey. CI, confidence interval; MTCT, mother-to-child transmission of HIV.
The rapid rollout of Option A in Zimbabwe precluded the use of a randomized impact evaluation. We responded to this challenge by estimating the overall impact of the intervention by comparing pre and postintervention samples; and capitalizing on naturally occurring variability in the duration of catchment area level exposure to Option A to examine impact heterogeneity. However, our analyses were unable to account for community-level confounders that might have affected both the exposure to the Option A activities and the probability of vertical transmission of HIV (e.g. changes in transportation infrastructure), as such data were not available. Further, we used a prepost design and assumed that differences in the unadjusted proportions of MTCT and HIV-free infant survival at 9-18 months between 2012 and 2014 were likely due to Option A. Although Option A is likely the major driver of the significant differences observed, there could be other unmeasured temporal factors such as epidemic trajectory, or other social or health system factors that could influence these outcomes. Nonetheless, several observed factors were examined and found not to be confounders: number of health staff, staff trained in Option A, and availability of CD4 þ cell count testing.
Our estimates account for transmissions occurring during the first 9-18 months of breastfeeding; however, 71% of HIV-exposed infants were still breastfeeding at the time of the 2012 survey and 78% in 2014 (median duration of breastfeeding in Zimbabwe is 17.8 months [21] ). Thus, HIV-free survival at 24 months (at the end of breastfeeding) could be lower, and MTCT might be higher. This is particularly relevant for the 2012 estimates, because before the implementation of Option A, breastfeeding HIV-infected women did not receive ARVs, in contrast to Option A in which these women continue receiving prophylaxis until the end of breastfeeding. Further, despite our efforts to enrol all eligible mother-infant pairs and to include verbal autopsy data, infant deaths may have been underreported. Moreover, maternal HIV status was measured at 9-18 months postpartum; however, some HIV-positive women might have become infected postpartum (assuming 2.9 per 100 woman-years incidence postpartum [22] , approximately 22 of 887 HIV-infected women at baseline, and 34 of 1160 at endline) and may have (appropriately) not received antiretroviral prophylaxis. Finally, data were only collected in five of 10 provinces (where 55% of the population of Zimbabwe live) [23] , although these were widely dispersed across the country and included major cities.
We assessed the population-level effect of Option A on MTCT and HIV-free infant survival at 9-18 months in Zimbabwe. Our findings support the impact of Option A, by demonstrating that this PMTCT regimen can be effective in a real-world setting. Moreover, the 2014 survey data presented here provide baseline estimates for estimating the impact of Option Bþ, which has been recently rolled out in Zimbabwe. A third cross-sectional survey will be conducted in 2017 in the same 157 catchment areas surveyed in 2012 and 2014, to obtain endline estimates of HIV-free infant survival and MTCT after 2 years of implementation of Option Bþ. This will provide a unique opportunity to compare the effectiveness of Options A and Bþ in the same setting. also thank our participants without whom this study would not have been possible.
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Option A improved HIV-free infant survival Buzdugan et al. 1661 Table 3 . Association between endline catchment area level HIV-free infant survival at 9-18 months and months since introduction of Option A; data from the impact evaluation of Zimbabwe's prevention of mother-to-child transmission program. Generalized linear model of the HIV-free survival at endline with a logit link, among 132 catchment areas. In addition to months since introduction of Option A, the model controlled for HIV-free survival at baseline and for the following catchment area level population and facility characteristics: urban vs. rural catchment area, number of health staff members, number of village health workers/health promoters, number of days per week the facility is open for antenatal care, the proportion of health staff that received training on Option A, and whether the facility had on site CD4 þ testing at baseline.
